Advertisement

Predictive Biomarkers and Targeted Therapies in Hepatic, Pancreatic, and Biliary Cancers

  • Steven Alexander Mann
  • Romil Saxena
Chapter

Abstract

Hepatic and pancreatobiliary cancers often present at advanced stages, and currently, there are very few approved therapeutic options. This chapter focuses on the predictive biomarkers for current therapies as well as selected alternative options that are currently being evaluated in Phase III trials for these malignancies. In a Phase III trial for advanced hepatocellular carcinoma (HCC), there was a significant improvement in overall survival for patients with elevated alpha-fetoprotein who received ramucirumab. A Phase II trial of glypican-3 (GPC3) peptide vaccines in HCC demonstrated lower recurrence rates in tumors that were GPC3-positive. Advanced HCC cases with high cellular mesenchymal-epithelial transcription factor (c-MET) expression have significantly improved overall survival on tivantinib. A study of adjuvant chemotherapy for pancreatic cancer reported improved survival in cases with low postoperative CA 19-9. High expression of human equilibrative nucleoside transporter 1 (hENT1) has been shown to predict significantly improved overall survival in both pancreatic cancer and cholangiocarcinoma after gemcitabine therapy. There are currently no predictive biomarker guidelines for hepatic, pancreatic, or biliary tumors. Additional clinical trials are required before consensus statements outlining the utility of biomarkers in the treatment of these cancers can be effectively formulated. Currently, there are many ongoing clinical trials designed to confirm and expand the roles of predictive biomarkers in hepatic and pancreatobiliary cancers. Incorporation of recent advances in molecular analysis and immunotherapy into clinical trials promises new hope for these dismal diagnoses.

Keywords

Alpha-fetoprotein CA 19-9 Cellular mesenchymal-epithelial transcription factor Cholangiocarcinoma Gemcitabine Glypican-3 Hepatocellular carcinoma Human equilibrative nucleoside transporter 1 Pancreatic ductal adenocarcinoma Predictive biomarkers 

References

  1. 1.
    Tsuchiya N, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21(37):10573–83.CrossRefPubMedGoogle Scholar
  2. 2.
    Khorana AA, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(21):2541–56.CrossRefPubMedGoogle Scholar
  3. 3.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRefPubMedGoogle Scholar
  4. 4.
    Sasaki H, et al. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer. 2014;111(7):1275–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Llovet JM, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290–300.CrossRefPubMedGoogle Scholar
  6. 6.
    Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2016;3:31–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Sawada Y, et al. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5(5):e1129483.CrossRefPubMedGoogle Scholar
  8. 8.
    Pievsky D, Pyrsopoulos N. Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date. J Hepatocell Carcinoma. 2016;3:69–76.CrossRefPubMedGoogle Scholar
  9. 9.
    Scaggiante B, et al. Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol. 2014;20(5):1268–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Chauhan R, Lahiri N. Tissue- and serum-associated biomarkers of hepatocellular carcinoma. Biomark Cancer. 2016;8(Suppl 1):37–55.PubMedGoogle Scholar
  11. 11.
    Humphris JL, et al. The prognostic and predictive value of serum CA19. 9 in pancreatic cancer. Ann Oncol. 2012;23(7):1713–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Viterbo D, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc. 2016;8(3):128–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014;20(26):8482–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Sinn M, et al. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – results from the CONKO-001 trial. Eur J Cancer. 2015;51(12):1546–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Han W, et al. Prognostic value of SPARC in patients with pancreatic cancer: a systematic review and meta-analysis. PLoS One. 2016;11(1):e0145803.CrossRefPubMedGoogle Scholar
  16. 16.
    Steffen JD, et al. Structural implications for selective targeting of PARPs. Front Oncol. 2013;3:301.CrossRefPubMedGoogle Scholar
  17. 17.
    Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Ther Adv Gastroenterol. 2017;10(1):132–41.CrossRefGoogle Scholar
  18. 18.
    El-Khoueiry AB, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineIndiana University School of MedicineIndianapolisUSA

Personalised recommendations